Halozyme Therapeutics, Inc. (HALO)
105.35
-1.57
(-1.47%)
USD |
NASDAQ |
Aug 28, 16:00
104.89
-0.46
(-0.44%)
After-Hours: 20:00
Halozyme Therapeutics Free Cash Flow : 806.22M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 806.22M |
| March 31, 2026 | 667.65M |
| December 31, 2025 | 644.59M |
| September 30, 2025 | 602.40M |
| June 30, 2025 | 540.69M |
| March 31, 2025 | 495.76M |
| December 31, 2024 | 468.37M |
| September 30, 2024 | 392.71M |
| June 30, 2024 | 408.32M |
| March 31, 2024 | 423.57M |
| December 31, 2023 | 373.28M |
| September 30, 2023 | 353.63M |
| June 30, 2023 | 292.79M |
| March 31, 2023 | 263.58M |
| December 31, 2022 | 235.30M |
| September 30, 2022 | 237.55M |
| June 30, 2022 | 290.16M |
| March 31, 2022 | 287.26M |
| December 31, 2021 | 297.98M |
| September 30, 2021 | 264.85M |
| June 30, 2021 | 149.51M |
| March 31, 2021 | 115.93M |
| December 31, 2020 | 52.95M |
| September 30, 2020 | -23.54M |
| June 30, 2020 | -60.14M |
| Date | Value |
|---|---|
| March 31, 2020 | -89.07M |
| December 31, 2019 | -89.46M |
| September 30, 2019 | -54.81M |
| June 30, 2019 | -43.38M |
| March 31, 2019 | -36.50M |
| December 31, 2018 | -54.16M |
| September 30, 2018 | 90.84M |
| June 30, 2018 | 130.20M |
| March 31, 2018 | 132.24M |
| December 31, 2017 | 132.70M |
| September 30, 2017 | -35.90M |
| June 30, 2017 | -65.17M |
| March 31, 2017 | -61.96M |
| December 31, 2016 | -53.52M |
| September 30, 2016 | -54.14M |
| June 30, 2016 | -62.29M |
| March 31, 2016 | -39.60M |
| December 31, 2015 | -39.44M |
| September 30, 2015 | -23.79M |
| June 30, 2015 | -20.02M |
| March 31, 2015 | -44.81M |
| December 31, 2014 | -48.89M |
| September 30, 2014 | -64.19M |
| June 30, 2014 | -63.37M |
| March 31, 2014 | -58.29M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Incyte Corp. | 1.890B |
| AVITA Medical, Inc. | -25.21M |
| Neurocrine Biosciences, Inc. | 812.00M |
| Iovance Biotherapeutics, Inc. | -296.40M |
| Editas Medicine, Inc. | -120.55M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 240.89M |
| Cash from Investing (Quarterly) | -62.66M |
| Cash from Financing (Quarterly) | -326.25M |
| Free Cash Flow Per Share (Quarterly) | 1.953 |
| Free Cash Flow to Equity (Quarterly) | 234.70M |
| Free Cash Flow to Firm (Quarterly) | 241.23M |
| Free Cash Flow Yield | 6.32% |